has been implicated in cell signaling pathways involved in left ventricular hypertrophy and heart failure, but its exact role has not been elucidated. In this study, replication-defective adenoviruses (Adv) encoding green fluorescent protein (GFP)-tagged, wild-type (WT), and mutant forms of PYK2 were used to determine whether PYK2 overexpression activates MAPKs, and downregulates SERCA2 mRNA levels in neonatal rat ventricular myocytes (NRVM). PYK2 overexpression significantly decreased SERCA2 mRNA (as determined by Northern blot analysis and real-time RT-PCR) to 54 Ϯ 4% of Adv-GFP-infected cells 48 h after Adv infection. Adv-encoding kinase-deficient (KD) and Y 402F phosphorylation-deficient mutants of PYK2 also significantly reduced SERCA2 mRNA (WTϾKDϾY 402F). Conversely, the PTK inhibitor PP2 (which blocks PYK2 phosphorylation by Src-family PTKs) significantly increased SERCA2 mRNA levels. PYK2 overexpression had no effect on ERK1/2, but increased JNK1/2 and p38 MAPK phosphorylation from fourfold to eightfold compared with GFP overexpression. Activation of both "stress-activated" protein kinase cascades appeared necessary to reduce SERCA2 mRNA levels. Adv-mediated overexpression of constitutively active (ca)MKK6 or caMKK7, which activated only p38 MAPK or JNKs, respectively, was not sufficient, whereas combined infection with both Adv reduced SERCA2 mRNA levels to 45 Ϯ 12% of control. WTPYK2 overexpression also significantly reduced SERCA2 promoter activity, as determined by transient transfection of a 3.8-kb SERCA2 promoter-luciferase construct. Thus a PYK2-dependent signaling cascade may have a role in abnormal cardiac Ca 2ϩ handling in left ventricular hypertrophy and heart failure via downregulation of SERCA2 gene transcription. signal transduction; heart failure; calcium; protein kinase C LEFT VENTRICULAR HYPERTROPHY (LVH) and its transition to heart failure (HF) are associated with numerous changes in myocardial gene expression and protein turnover. Of particular interest, many investigators have documented a significant reduction in sarco(endo)plasmic reticulum Ca Despite the potential negative impact of SERCA2 downregulation on cardiac structure and function, relatively few studies have addressed the mechanisms and signal transduction pathways responsible for these changes. Both transcriptional (1, 2, 17, 40, 48, 49, 53) and posttranscriptional (30, 31, 37, 39, 51) mechanisms may be involved, although the specific effectors responsible for SERCA2 downregulation are only now being identified. In a previous study from our laboratory (6), we showed that decreasing [Ca 2ϩ ] i by blockade of voltagegated, L-type Ca 2ϩ channels substantially increased basal SERCA2 mRNA and protein levels in neonatal rat ventricular myocytes (NRVM), and stimulated sarcoplasmic reticulum Ca 2ϩ uptake, resulting in a twofold increase in the rate of [Ca 2ϩ ] i decline. In contrast, cyclic stretch of noncontracting NRVM substantially downregulated SERCA2 mRNA and protein levels via a mechanism independent of Ca 2ϩ influx via voltage-gated, L-type Ca 2ϩ channels (12). Furthermore, we and others (15, 16, 21, 36, 37) MAPK signaling pathway also caused the transcriptional downregulation of SERCA2 promoter activity. However, the specific components linking Ca 2ϩ , cyclic stretch, and PKCs to the MAPK signaling pathways that regulate SERCA2 levels in cardiomyocytes remain unknown.
LEFT VENTRICULAR HYPERTROPHY (LVH) and its transition to heart failure (HF) are associated with numerous changes in myocardial gene expression and protein turnover. Of particular interest, many investigators have documented a significant reduction in sarco(endo)plasmic reticulum Ca 2ϩ ATPase (SERCA2) gene expression in ventricular tissue of experimental animals and patients with LVH and HF (for review, see Ref. 22) . SERCA2 downregulation clearly has functional consequences in the HF state because even small alterations in the number of sarcoplasmic reticulum (SR) Ca 2ϩ pumps can affect SR Ca 2ϩ load, and thereby affect, in part, the concentration of released Ca 2ϩ available for cardiomyocyte contraction (18, 23) . SERCA2 downregulation also prolongs the intracellular [Ca 2ϩ ] ( [Ca 2ϩ ] i ) transient, and thus increases the diastolic level of [Ca 2ϩ ] i , which may in turn activate Ca 2ϩ -dependent signaling pathways involved in the induction of cardiomyocyte hypertrophy (32) and apoptosis (57) .
Despite the potential negative impact of SERCA2 downregulation on cardiac structure and function, relatively few studies have addressed the mechanisms and signal transduction pathways responsible for these changes. Both transcriptional (1, 2, 17, 40, 48, 49, 53) and posttranscriptional (30, 31, 37, 39, 51) mechanisms may be involved, although the specific effectors responsible for SERCA2 downregulation are only now being identified. In a previous study from our laboratory (6), we showed that decreasing [Ca 2ϩ ] i by blockade of voltagegated, L-type Ca 2ϩ channels substantially increased basal SERCA2 mRNA and protein levels in neonatal rat ventricular myocytes (NRVM), and stimulated sarcoplasmic reticulum Ca 2ϩ uptake, resulting in a twofold increase in the rate of [Ca 2ϩ ] i decline. In contrast, cyclic stretch of noncontracting NRVM substantially downregulated SERCA2 mRNA and protein levels via a mechanism independent of Ca 2ϩ influx via voltage-gated, L-type Ca 2ϩ channels (12) . Furthermore, we and others (15, 16, 21, 36, 37) have shown that one or more isoenzymes of protein kinase C (PKC) are critical factors regulating SERCA2 gene expression in response to neurohormonal stimuli. For instance, Ho et al. (21) previously showed that phorbol myristate acetate (PMA), a potent activator of PKC-␣, -␤, -␦, and -⑀ in cardiomyocytes, downregulated SERCA2 and prolonged the [Ca 2ϩ ] i transient via activation of the Raf-MEK1-ERK1/2 pathway. Similarly, Andrews et al. (1) demonstrated that activation of the MKK6-p38 MAPK signaling pathway also caused the transcriptional downregulation of SERCA2 promoter activity. However, the specific components linking Ca 2ϩ , cyclic stretch, and PKCs to the MAPK signaling pathways that regulate SERCA2 levels in cardiomyocytes remain unknown.
The Ca 2ϩ -dependent, nonreceptor protein tyrosine kinase (PTK) proline-rich tyrosine kinase 2 (PYK2) is a member of the focal adhesion kinase (FAK) family of nonreceptor PTKs. PYK2 coordinates Ca 2ϩ -, integrin-, and PKC-dependent signaling pathways in some tissues (for review, see Ref. 3) . PYK2 expression and/or phosphorylation are regulated by [Ca 2ϩ ] i and PKCs in cardiomyocytes and vascular smooth muscle cells (7, 8, 41) . As examined in various cell types, PYK2 acts as an important scaffolding protein, and transduces signals from G protein-coupled receptors to downstream MAPK signaling pathways depending on which signaling kinases and adapter proteins bind to the phosphorylated enzyme (10, 34) . PYK2 has also been shown to link a variety of stressful stimuli, including Ca 2ϩ overload, UV irradiation, and TNF-␣ treatment to MAPK activation in several cell types (50) . Recently, Hirotani et al. (20) demonstrated that PYK2 is an essential signaling component in endothelin-and phenylephrine-induced NRVM hypertrophy, perhaps acting via the Ca 2ϩ -and/or PKC-dependent activation of Rac1.
We (9) previously demonstrated that PYK2 expression and phosphorylation were significantly increased in adult rat ventricular myocytes in vivo during the transition from LVH to HF coincident with SERCA2 downregulation. Similarly, Melendez et al. (29) showed that PYK2 expression and phosphorylation were increased in a mouse model of dilated cardiomyopathy, but its exact role in these conditions has not been elucidated. In this study, we utilized replication-defective adenoviruses (Adv) encoding wild-type and mutant forms of PYK2 to interrogate their effects on cell growth, MAPK activation, and SERCA2 gene expression in NRVM. These data are presented to suggest a novel, and potentially important negative feedback mechanism regulating [Ca 2ϩ ] i levels in cardiomyocytes.
MATERIALS AND METHODS
Reagents. PC-1 tissue culture medium was obtained from BioWhittaker (Walkersville, MD). Dulbecco's modified Eagle's medium (DMEM) and medium 199 were obtained from GIBCO-BRL (Grand Island, NY). PYK2 and paxillin monoclonal antibodies (mAb) were obtained from Transduction Laboratories (Lexington, KY) and Upstate Biotechnologies (Lake Placid, NY). Rhodamine-conjugated goat anti-mouse IgG was obtained from Molecular Probes (Eugene, OR). Phosphospecific PYK2-Y 402 mAb was purchased from Biosource (Camarillo, CA). Phospho-specific ERK and JNK polyclonal antibodies (pAb) were from Promega (Madison, WI) and phospho-specific p38 MAPK , total SAPK/JNK, and total p38 MAPK pAb were from Cell Signaling (Beverly, MA). Antibodies for total ERK1/2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Real-time RT-PCR reagents were obtained from Amersham Biosciences and Invitrogen (Carlsbad, CA). cDNA primers and probes were obtained from Integrated DNA Technologies (Coralville, IA). 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolol [3,4-d] pyrimidine (PP2) was obtained from Calbiochem (La Jolla, CA). All other reagents were of the highest grade commercially available and were obtained from Sigma (St. Louis, MO) and Baxter S/P (McGaw Park, IL).
Cell culture. The animals were handled in accordance with the American Physiological Society "Guiding Principles in the Care and Use of Animals." All procedures involving the animals were approved by the Institutional Animal Care and Use Committee of Loyola University Medical Center. NRVM were isolated as previously described (42) . NRVM were plated at a density of 400, 1,000, or 1,600 cells/mm 2 onto collagen-coated 35, 60, or 100 mm dishes, or one-well Permanox chamberslides, and left undisturbed in a 5% CO2 incubator for 18 -24 h. Attached cells were maintained in DMEM/medium 199 (4:1) containing antibiotic/antimycotic solution. Under these serumfree culture conditions, NRVM displayed synchronous [Ca 2ϩ ]i transients and beating activity (ϳ100 -150 beats/min) within 24 h after being plated.
Adenoviral constructs. Replication-deficient Adv encoding WT and mutant forms of PYK2 were generated as previously described (27) . Briefly, PYK2 cDNAs (kindly provided by J. T. Parsons, University of Virginia) were subcloned in frame into pEGFP-C1 vector (BD Biosciences-Clontech, Palo Alto, CA). The WTPYK2 contained the entire 1,009 amino acid coding sequence of rat PYK2 (43) . The kinase-defective (KD) mutant consisted of a single amino acid substitution (K457A) within the central catalytic domain. The autophosphorylation site mutant consisted of a single amino acid substitution (Y 402F), which is required for Src-family kinase binding. The green fluorescent protein (GFP)-tagged PYK2 inserts were then sequentially subcloned into pShuttle-CMV plasmid, and then pAdeno-X viral DNA (BD Biosciences-Clontech). Linearized pAdeno-XϩGFP-PYK2 sequences were transfected into HEK-293 cells, and the resulting WT and mutant PYK2 Adv were amplified and purified by double CsCl gradient centrifugation. Replication-defective Adv encoding constitutively active (ca)MKK6 and caMKK7 were kindly provided by Dr. Yibin Wang (University of California at Los Angeles) (54, 55) , whereas a replication-defective Adv encoding caMEK1 was kindly provided by Dr. Jeffrey Molkentin, University of Cincinnati (11) . An Adv-expressing GFP (Adv-GFP) and an Adv-expressing nuclear-encoded (ne) ␤-galactosidase (Adv-ne␤gal) were used to control for nonspecific effects of Adv infection. The multiplicity of viral infection (MOI) was determined by dilution assay in human embryonic kidney (HEK)-293 cells grown in 96 well clusters. Cardiomyocytes were infected (60 min, 25°C with gentle agitation) with each Adv diluted in DMEM/medium 199. The medium was then replaced with virus-free DMEM/medium 199, and the cells cultured for an additional 8, 24, or 48 h.
Protein content and cell size. For the analysis of NRVM protein content, cells were quantitatively scraped from dishes in 0.2 N perchloric acid (1 ml) and collected by centrifugation (10,000 g, 10 min). The precipitate was redissolved by incubation (60°C, 20 min) in 250 l of 0.3 N KOH. Aliquots were used for analysis of total protein by the Lowry method with crystalline human serum albumin as standard, and for DNA using 33258 Hoechst dye and salmon sperm DNA as standard (46) . For determination of cell surface area, cardiomyocytes were first loaded with 2Ј7Ј-bis (2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF)-AM [2 M in a modified Krebs medium composed of (in mM) 135 NaCl, 5.9 KCl, 1.5 CaCl 2, 1.2 MgCl2, 11.5 glucose, and 11.6 HEPES, pH 7.3, supplemented with 0.1% BSA and 0.2% Pluronic F-127 detergent] for 1 h, followed by 1-h incubation in BCECF-free Krebs buffer. Cells were viewed with a laser scanning confocal microscope (model LSM 510, Zeiss). Optical sections through the base of the cells (ϳ20 cells/field) were stored as digital images and analyzed with Image-1 software (Universal Imaging, West Chester, PA). A binary mask was created by setting the threshold brightness that distinguished the fluorescent cells from the black background. Cell area was determined as an exact count of the number of pixels that made up the object's binary mask multiplied by the area of a unit pixel (46) .
Cell fixation and confocal microscopy. NRVM grown on chamberslides were infected with Adv-GFP or Adv-GFPWTPYK2 (10 MOI, 48 h). Cells were fixed, permeabilized, and stained with anti-paxillin mAb, as previously described (13, 14) . Fluorescently labeled cells were viewed with a Zeiss LSM 510 confocal microscope.
Western blot analysis. NRVM were homogenized in lysis buffer (44) . Equal amounts of extracted proteins (50 g) were separated by SDS-PAGE and Western blot analysis on 7.5% or 10% polyacrylamide gels. Primary antibody binding was detected with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit secondary antibody, and visualized by enhanced chemiluminescence (Amersham, Arlington Heights, IL).
mRNA analysis. Total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA was quantified by absorbance at 260 nm, and its integrity was determined by examining the 28S and 18S rRNA bands in ethidium bromide-stained agarose gels. SERCA2 and GAPDH mRNA levels were then analyzed with Northern blots or by real-time RT-PCR, as previously described (12, 36) .
SERCA2 promoter activity. NRVM plated at a density of ϳ1,000 cells/mm 2 were transiently transfected with a SERCA2 promoter plasmid construct pGL3-b-S2-HindIII/HincII (kindly provided by Dr.
Warner Simonides, VU University Medical Center, Amsterdam) (53) . The plasmid contained a fragment from the rat SERCA2 promoter (-3,263/ϩ550 bp from the transcriptional start site) linked to the firefly luciferase reporter gene. A control plasmid, containing the Rous sarcoma virus-long terminal repeat (RSV-LTR), linked to a bacterial ␤gal reporter gene (kindly provided by Dr. Edward Kislauskis, University of Massachusetts Medical Center) was used in conjunction with the SERCA2 plasmid to control for transfection efficiency. Cells were transfected with 5 g of the SERCA2 promoter plasmid along with 0.5 g of control RSV-LTR ␤gal. The plasmids were added to 4:1 medium free of both serum, as well as antibiotic/antimycotic agents, in the presence of 10 l/ml Lipofectamine 2000 reagent (Invitrogen Life Technologies, Carlsbad, CA). Cells were treated with the transfection cocktail for 6 h, and were then maintained in serumfree, 4:1 medium containing antibiotic/antimycotic agents for up to 72 h. SERCA2 promoter activity was assessed using the protocol described in the Luciferase Assay System (Promega, Madison, WI). Briefly, 4:1 medium were removed and 300 l of 1 ϫ reporter lysis buffer were added to the cells. The cells were then quick-frozen in a methanol/dry ice bath and allowed to thaw on ice. Cells were scraped into prechilled 1.5-ml Eppendorf tubes, briefly vortexed, and then centrifuged at 12,000 g for 2 min at 4°C. Supernatants were transferred into a fresh set of tubes and maintained on ice. A manual luminometer (Lumat LB 9501, Berthold Systems, Aquilippa, PA) was used to measure luciferase activity. For each sample, 100 l of luciferase assay reagent were added to 50 l of cell lysate, and luminescence was measured over a 30-s period. Detection of RSV-LTR ␤gal activity in cell lysates was performed using a ␤gal detection kit (catalog no. MO255, Marker Gene Technologies). Briefly, 20-l aliquots of cell lysates were pipetted into individual wells in opaque 96-well plates. One hundred microliters of reaction buffer (100 mM NaPO 4, 1 mM MgCl2, 10 mM ␤-mercaptoethanol, and 0.1% Triton X-100, pH 7.0) were added to each well. The fluorogenic substrate reagent 3-carboxyumbellifery ␤-D-galactopyranoside (50 l, 5 mM) was added and samples were allowed to incubate (20 min) at room temperature. Stop buffer (500 mM glycine and 10 mM EDTA, pH 12.0; 100 l) was then added and samples were allowed to incubate (10 min) at room temperature. Fluorescence values were measured on a Synergy HT Multi-Detection Plate Reader (Bio-Tek Instruments, Winooski, VT) using 390-nm excitation and 460-nm emission wavelengths. Promoter activity was reported as the ratio of luciferase luminescence values to ␤-galactosidase fluorescence values.
Data analysis. Results were expressed as means Ϯ SE. Normality was assessed using the Kolmogorov-Smirnov test, and homogeneity of variance was assessed using Levene's test. Data from multiple groups were compared with one-way ANOVA, or one-way ANOVA on ranks, followed by Dunnett's test, or Student-Newman-Keuls test, where appropriate. Data from two groups were compared by paired t-test, or Wilcoxon's signed-rank test where appropriate. Differences among means were considered significant at P Ͻ 0.05. Data were analyzed using SigmaStat version 1.0 (Jandel Scientific, San Rafael, CA).
RESULTS

GFPWTPYK2 localization and expression in NRVM.
NRVM were infected (10 MOI, 48 h) with Adv-GFPWT-PYK2, and then fixed, permeabilized, counterstained with a mAb specific for paxillin, followed by rhodamine-conjugated goat anti-mouse IgG, and viewed under a laser-scanning con- focal microscope. As shown in Fig. 1A , GFPWTPYK2 was predominantly distributed diffusely throughout the cytoplasm and was excluded from the cell nucleus, which was similar to the localization of endogenous PYK2 in neonatal and adult cardiomyocytes (7) . However, PYK2 was also detected in some centrally arranged focal adhesions, as indicated by colocalization with the cytoskeletal adaptor protein paxillin.
Cell extracts from comparably infected NRVM were then examined for PYK2 expression and tyrosine phosphorylation at Y 402 . Endogenous PYK2 (106 -110 kDa) was detected at relatively low levels in cells infected with Adv-GFP, whereas a prominent protein band of ϳ140 kDa was detected in cells as early as 8 h after infection with Adv-GFPWTPYK2 (Fig. 1B,  top blot) . Additional protein bands were detected at later time points after Adv infection. The same samples were then probed with an antibody specific for PYK2 phosphorylated at Y 402 (Fig. 1B, bottom blot) . Relatively little phosphorylated, endogenous PYK2 was detected in NRVM infected with the control Adv-GFP. However, the overexpressed, ϳ140 kDa protein was readily detected using the phosphospecific antibody. This polypeptide also cross-reacted with an anti-GFP antibody (data not shown). These results suggested that WTPYK2 overexpression substantially increased the amount of active PYK2 in cardiomyocytes, and thereby stimulated PYK2-dependent signaling.
GFPWTPYK2 expression alone does not cause NRVM hypertrophy. The effect of WTPYK2 overexpression on NRVM protein content and cell size were then examined. Total protein (g/dish), DNA (g/dish), and total protein/DNA ratio ( Fig.  2A) were similar in uninfected, Adv-GFP-infected, and Adv-GFPWTPYK2-infected NRVM. Cell surface area (m 2 /cell; Fig. 2B ) was also unaffected. In contrast, the hypertrophic agent phorbol myristate acetate (PMA; 200 nM, 24 h) increased total protein/DNA ratio and cell size to a similar extent in each group. These data indicate that WTPYK2 overexpression alone was not sufficient to induce NRVM hypertrophy, but WTPYK2 overexpressing cells were still capable of undergoing hypertrophy in response to a hypertrophic stimulus.
GFPWTPYK2 overexpression downregulates SERCA2 mRNA levels. We next examined the effects of GFPWTPYK2 overexpression on SERCA2 mRNA levels in Northern blotting experiments. As seen in Fig. 3A , Adv-GFPWTPYK2 (10 MOI, 48 h) substantially reduced SERCA2 mRNA levels, compared with cells infected with Adv-GFP (10 MOI, 48 h). At this relatively low MOI, Adv infection alone had no apparent effect, as SERCA2 mRNA levels were similar in uninfected, control cells, and cells infected with Adv-GFP. The extent of SERCA2 downregulation was similar to that observed with PMA (16, 36, 38) .
To obtain a more sensitive and quantitative assessment of these relatively modest changes in gene expression, the effects WTPYK2 overexpression on SERCA2 mRNA levels (relative to GAPDH mRNA) were analyzed by real-time RT-PCR, and the results of five experiments are depicted in Fig. 3B . Both PMA and Adv-GFPWTPYK2 significantly decreased SERCA2 mRNA levels to 42 Ϯ 9% and 54 Ϯ 4% of uninfected, control NRVM, respectively. In four additional experiments, we analyzed the time course of SERCA2 downregulation after Adv infection (5 MOI, 8 -48 h) with either Adv-GFP or Adv-GFP-WTPYK2. As seen in Fig. 3C , SERCA2 mRNA levels progressively decreased over time coincident with the time course of GFP-WTPYK2 overexpression and phosphorylation (Fig. 1B) .
Inhibition of PYK2 increases basal SERCA2 mRNA levels. We (8) previously demonstrated that the highly specific Srcfamily PTK inhibitor PP2 reduced basal, endothelin-and caPKC-⑀-induced PYK2 activation in NRVM. Therefore, we next examined whether inhibition of Src-family PTKs affected Fig. 2 . GFP-WT-PYK2 expression alone does not cause NRVM hypertrophy. A: NRVM were maintained under control conditions (uninfected; UI) or infected (10 MOI) with either Adv-GFP or Adv-GFPWTPYK2. After 24 h, the dishes were then maintained in either control medium lacking phorbol myristate acetate (ϪPMA) or stimulated with the hypertrophic agent PMA (ϩPMA, 200 nM). Total protein/DNA ratio (g/g) was then analyzed in cell extracts 24 h later. Data are the means Ϯ SE for triplicate determinations of total protein/DNA ratio from 6 experiments. B: similarly treated NRVM were dye loaded with BCECF-AM, and cell surface area (m 2 ) analyzed by confocal microscopy and image analysis. Data are means Ϯ SE of 1,135-1,156 cells derived from 3 different cell isolations. There was no significant difference in protein/DNA ratio or surface area between the UI, GFP-treated, or WT-PYK2-treated groups. However, ϩPMA significantly (ϩP Ͻ 0.05) increased protein/ DNA and surface area vs. ϪPMA cells in UI, GFP-, and WTPYK2-expressing cells.
SERCA2 mRNA levels in these high-density, spontaneously contracting NRVM cultures. As seen in Fig. 4 , PP2 (50 M; 48 h) significantly increased SERCA2 mRNA levels 2.9-fold compared with untreated NRVM. However, PMA was still able to downregulate SERCA2 mRNA levels to 53 Ϯ 11% of untreated NRVM, which is similar to the level of SERCA2 mRNA downregulation observed with WTPYK2 overexpression in the absence of PP2, or with PMA (Fig. 3) .
Effects of mutant forms of PYK2 on SERCA2 mRNA levels. PYK2 contains a central catalytic domain, as well as an NH 2 terminal autophosphorylation site (Y 402 ) required for Srcfamily PTK binding. When activated in response to an increase in [Ca 2ϩ ] i in PC12 cells, PYK2 undergoes a bimolecular, transautophosphorylation reaction, leading to the phosphorylation of the kinase at Y 402 , subsequent recruitment and activation of Src, which in turn phosphorylates the kinase domain and enhances PYK2 kinase activity (35) . Therefore, we examined whether mutations within the kinase domain or the Y 402 site affected SERCA2 gene expression in NRVM. As seen in Fig. 5A , overexpression of kinase-inactive, GFPKDPYK2 increased the amount of PYK2 immunoreactive protein. Interestingly, the overexpressed GFP-KDPYK2 mutant underwent efficient tyrosine phosphorylation at Y 402 , despite the fact that the catalytic domain was rendered inactive by a point mutation (K457A) within its active site. Adv-GFP-Y 402 FPYK2 also caused the overexpression of a ϳ140-kDa PYK2 transgene. However, the transgene was not detected with the phosphospecific PYK2-Y 402 antibody, consistent with the fact that this site was indeed mutated. Nevertheless, WTPYK2 and both mutants significantly reduced SERCA2 mRNA levels (WTϾKDϾY 402 F) (Fig. 5, B and C MAPK activation have been implicated in regulating SERCA2 gene expression in cardiomyocytes (1, 21) . Therefore, we next examined the effects of PYK2 overexpression on ERKs, JNKs, and p38 MAPK in NRVM. Adv-GFPWT-PYK2 had no significant effect on ERK1/2 phosphorylation (Fig. 6A) , but increased the activation of JNK1/2 ( Fig. 6B ) and p38 MAPK (Fig. 6C) , as detected by Western blot analysis with their corresponding phosphospecific antibodies. Steady-state protein levels of all three MAPKs were unaffected compared with NRVM infected with Adv-GFP. The quantitative analysis of 10 Western blotting experiments is also depicted. As is evident from the figure, both SAPKs were substantially activated (4 to 8 fold) in response to WTPYK2 overexpression.
Because PYK2 overexpression activated JNKs and p38 MAPK , we examined whether activation of either or both SAPKs was sufficient to downregulate SERCA2 mRNA levels. NRVM were infected with a control Adv (Adv-ne␤gal; 10 MOI, 48 h), and either Adv-caMKK6 or Adv-caMKK7 (10 MOI, 48 h), which are upstream regulators of p38 MAPK and JNK1/2, respectively. An Adv-expressing caMEK1, an upstream activator of ERK1/2, was used as a positive control for MAPK-dependent SERCA2 downregulation in NRVM (21) . Cells were then examined for MAPK activation with Western blot analysis (Fig. 7A ) and for SERCA2 mRNA levels by real-time RT-PCR (Fig. 7B) . As shown in the figure, caMEK1 activated ERKs (Fig. 7A) and was sufficient to downregulate SERCA2 mRNA levels to 61 Ϯ 10% of Advne␤gal infected NRVM (Fig. 7B) . Neither caMKK6 nor caMKK7 activated ERKs in NRVM, but each caMKK activated its appropriate SAPK (Fig. 7A) . However, neither SAPK alone was sufficient to downregulate SERCA2 mRNA levels (Fig. 7B ). In contrast, infection with both Adv-caMKK6 and Adv-caMKK7 (10 MOI for each Adv, 48 h) concomitantly activated both p38 MAPK and JNK1/2 (Fig. 7A) , and also significantly downregulated SERCA2 mRNA levels to 45 Ϯ 12% of Adv-ne␤gal-infected, control cells (20 MOI, 48 h; Fig. 7C) .
Effects of PYK2 and PMA on SERCA2 promoter activity. Previous studies (1, 21) have indicated that MAPKs downregulate SERCA2 gene expression at the level of gene transcription. To determine whether PYK2 overexpression mediates its effect on SERCA2 mRNA levels by decreasing SERCA2 promoter activity, NRVM were transfected with a 3.8-kb SERCA2 promoter-luciferase reporter plasmid (along with an RSV-LTR ␤gal reporter construct to control for any differences in transfection efficiency), and were then infected with either Adv-GFP or Adv-GFPWTPYK2 (10 MOI, 24 h). Paired plates were then maintained in control medium, or medium containing PMA (200 nM) for an additional 24 h before analysis of cellular extracts for luciferase and ␤gal activities. As shown in Fig. 8 , NRVM overexpressing WTPYK2 had significantly decreased SERCA2 promoter activity, compared with cells infected with Adv-GFP. PMA reduced SERCA2 promoter activity in Adv-GFP infected cells, but did not further reduce SERCA2 promoter activity in cells overexpressing WTPYK2.
DISCUSSION
In this report, we have identified a novel, and potentially important signaling pathway that regulates SERCA2 gene expression and [Ca 2ϩ ] i handling in cardiomyocytes. When overexpressed, WTPYK2, a Ca 2ϩ -dependent, nonreceptor PTK, was sufficient to downregulate SERCA2 gene expression in NRVM. Conversely, the PTK inhibitor PP2 was sufficient to significantly increase basal SERCA2 mRNA levels in spontaneously contracting NRVM. PYK2 is known to integrate signals arising from a variety of different stimuli in cardiomyocytes via alterations in [Ca 2ϩ ] i and/or activation of PKCs (7, 8, 25, 29 ). Here we demonstrate that PYK2 may also regulate the expression of a critical, membrane Ca 2ϩ pump, thereby affecting [Ca 2ϩ ] i regulation and adding to the complexity of this signaling web.
In previous studies (6, 12, 36, 37) , we demonstrated that mechanical loading, [Ca 2ϩ ] i , and PKCs are all important regulators of SERCA2 gene expression. Ca 2ϩ influx via L-type Ca 2ϩ channels substantially reduced SERCA2 mRNA and protein levels, and prolonged the time constant for relaxation of the [Ca 2ϩ ] i transient compared with verapamil-treated NRVM (6). Our present results now provide a potential explanation for these findings, in that Ca 2ϩ channel blockade markedly decreased PYK2 phosphorylation (8) and expression (7), thus eliminating a key component of a signaling pathway that may be important in regulating SERCA2 levels. Similarly, SERCA2 mRNA levels were increased by treating spontaneously contracting NRVM with the PKC inhibitors staurosporine and chelerythrine (37) , and by overexpressing dominantnegative inhibitors of individual PKC isoenzymes (36), thereby inhibiting potential activators of a PYK2-dependent signal transduction pathway (8) . It is also interesting to note that increasing Ca 2ϩ influx/release activates PYK2 in many cell types, including NRVM (8, 29) . Electrical stimulation of contraction also caused increased [Ca 2ϩ ] i , and caused the membrane translocation of PKC-⑀ and PKC-␦ (47), thus providing additional links to the SERCA2 regulatory pathway.
PYK2 overexpression appeared to mediate SERCA2 downregulation via activation of the JNK and p38 MAPK cascades. PYK2 has been identified as a potential upstream regulator of both SAPKs in NRVM (28) , as well as in other cell types. For example, Tokiwa et al. (50) showed that WTPYK2 overexpression activated JNKs in PC12 cells, whereas a dominantnegative mutant of PYK2 interfered with UV light-or osmotic shock-induced activation of JNKs. Furthermore, Kodama et al. (24) demonstrated that ET-induced JNK activation in NRVM was mediated primarily via the PKC-and Ca 2ϩ -dependent http://ajpcell.physiology.org/ activation of PYK2. PYK2 was found to associate with active Src, and the adapter proteins p130 Cas and Crk, which are involved in SAPK activation in a variety of cells. In cardiac fibroblasts, angiotensin II-induced JNK activation was also dependent upon PYK2 via GTP-loading of Rac1 (33) . A similar PYK2-dependent pathway was necessary for endothelin-induced activation of p38 MAPK in human and rat mesangial cells (45) . Finally, we (27) recently demonstrated in cultured chondrocytes that soluble fibronectin fragments activated a ␣ 5 ␤ 1 -integrin-dependent signaling pathway involving PKC-␦, PYK2, JNKs, and p38
MAPK , leading to stimulation of MMP-13 promoter activity and expression. Thus it seems likely that PYK2 activates the JNK and p38
MAPK cascades via similar mechanisms in NRVM.
We found that specific functional domains within PYK2 were important in downregulating SERCA2 mRNA levels. We found that mutations at the putative autophosphorylation site and within the kinase domain decreased (but did not eliminate) the ability of PYK2 to elicit these effects. In fact, the kinase activity of the overexpressed transgene appeared to contribute relatively little to SERCA2 downregulation, as the GFPKD-PYK2 mutant underwent efficient phosphorylation at Y 402 despite a mutation that rendered the kinase catalytically inactive. Similar results were obtained by Lakkakorpi et al. (26) , who found that in osteoclasts, PYK2 kinase activity was dispensable for efficient tyrosine phosphorylation at Y 402 as well as at other sites. These data suggest that in some cell types, PYK2 can be phosphorylated at Y 402 by another kinase, perhaps a member of the Src-family of PTKs. Of note, we recently demonstrated that basal and endothelin-induced phosphorylation of PYK2 at Y 402 was inhibited by PP2, a relatively specific Src-family PTK inhibitor (8) . It is also possible that the catalytically inactive, GFPKDPYK2 transgene underwent Y 402 phosphorylation via bimolecular autophosphorylation involving the endogenous enzyme, as was recently demonstrated to occur in PC12 cells and Src/Yes/Fyn-deficient fibroblasts (35) . In contrast to the kinase-deficient mutant, SERCA2 downregulation were nearly prevented by overexpression of PYK2 bearing the Y 402 F mutation. Phosphorylation of Y 402 provides a docking site for Src-family PTKs to bind to and phosphorylate PYK2 at other sites, including Y 579 , Y 580 , and Y 881 . Lakkakorpi et al. (26) also showed that overexpressed Y 402 FPYK2 was only weakly phosphorylated at these additional sites, and therefore functioned as a dominant-negative inhibitor of PYK2-dependent cell spreading and bone resorption in osteoclasts. Furthermore, PP2 (which blocks PYK2 phosphorylation at Y 402 ) substantially increased basal SERCA2 mRNA levels in NRVM (Fig. 4) . Taken together, these results suggest that the PYK2/Src complex is both necessary and sufficient to generate downstream signals that are important in regulating SERCA2 gene expression in cardiomyocytes.
Our results differ somewhat from a recent study by Andrews et al. (1) (Fig. 7) , basal levels of JNK1/2 activation in their cells may have been relatively higher than in our experiments, therefore accounting for this difference. Nevertheless, our results indicating that PYK2 can mediate activation of the JNK and p38 MAPK cascades support other studies, and confirm recently published work by Melendez et al. (28) indicating that PYK2 activates JNKs and p38 MAPK in cardiomyocytes. Taken together, these studies provide a potential upstream link between integrin-, Ca 2ϩ -, and PKC-dependent pathways leading to SAPK activation and SERCA2 downregulation in cardiomyocytes.
PYK2 overexpression substantially reduced SERCA2 promoter activity, suggesting that PYK2-dependent signaling pathways reduced SERCA2 gene expression by decreasing the rate of SERCA2 transcription. PMA, a potent activator of both Ca 2ϩ -dependent (i.e., PKC-␣ and PKC-␤) and Ca 2ϩ -independent (i.e., PKC-␦ and PKC-⑀) PKC isoenzymes, also reduced SERCA2 promoter activity. Of note, PMA substantially activates all three MAPK cascades in NRVM, although their degree of activation by physiological stimuli is in part dependent on which PKC isoenzymes are differentially activated (19, 47, 52) . However, PP2 did not prevent PMA-induced SERCA2 downregulation, suggesting that there is a PKC-dependent, but PYK2-independent pathway that also regulates SERCA2 promoter activity in NRVM. The most likely explanation for these data is that PMA activates a PKC-⑀/MEK1/ERK signaling cascade independently of PYK2 (19, 36, 46) . However, additional studies using physiological agonists and highly specific inhibitors of the individual PKCs and MAPKs will be necessary to fully evaluate these complex signaling pathways.
A potential concern of our studies is that PYK2-and SAPKmediated SERCA2 downregulation may be part of a more generalized change in mRNA expression in a compromised cardiomyocyte preparation. Indeed, prolonged PYK2 overexpression can trigger apoptosis in some cell culture systems (56) , including NRVM (28), and both p38 MAPK and JNKs have been implicated in the induction of cardiomyocyte apoptosis (5). We found that WTPYK2 overexpression had no significant effect on cardiomyocyte attachment, protein and DNA content, or the ability of the cells to respond to a hypertrophic stimulus, at least over the time course of these relatively brief cell culture experiments. Quantitative analysis of SERCA2 mRNA was consistently compared with that of another mRNA (GAPDH mRNA), and GAPDH mRNA levels did not systematically change relative to total RNA. Nevertheless, much of the data presented above provide only circumstantial evidence that PYK2 and SAPKs are important regulators of SERCA2 gene expression in NRVM. Although experiments utilizing PP2 suggest that PYK2 and Src-family PTKs are indeed involved, these inhibitors may be nonspecific. Furthermore, the majority of our studies utilize a "gain-of-function" approach to analyze potential, interacting signaling pathways. It is conceivable that overexpression of wild-type or constitutively active signaling kinases induces promiscuous, nonphysiological responses by causing phosphorylation reactions and complexation of signaling proteins that may not normally occur in response to the intricate, redundant signaling pathways operative in the intact heart. Overexpression of kinase-inactive, and phosphorylationsite mutant forms of PYK2, which function as dominantnegative inhibitors of PYK2 signaling in other cell types (4, 27, 50) , is also problematic in NRVM because these molecules appear to still generate specific (or nonspecific) signals via their scaffolding function in the cell. Additional studies using highly specific, pharmacological inhibitors of PYK2 autophosphorylation, or "knockdown/knockout" strategies will be needed to fully define the role of this signaling kinase in the altered gene expression that accompanies LVH and HF.
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